Table 1.
Probe Drug, Intrathecal, nmol | ED50 Clonidine (95% CI) |
ED50 Dexmedetomidine (95% CI) |
Interaction | |
Figure 1, ICR mice | Single drug | 3.0 (2.1–3.9) | 3.8 (1.3–6.3) | |
Clonidine–dexmedetomidine, 1:1 ratio | Synergistic | |||
Observed combination | 0.0045 (0.0001–0.0183)* | |||
Theoretical additive | 1.7 (1.3–2.1) | |||
Figure 2, α2AAR-WT | Single drug | 1.2 (0.45–1.9) | 1.0 (0.43–1.7) | |
Clonidine–dexmedetomidine, 1:1 ratio | Synergistic | |||
Observed combination | 0.18 (0.1–0.26)* | |||
Theoretical additive | 0.54 (0.34–0.74) | |||
Figures 4A and B, α2CAR-WT | Single drug | 1.7 (1.3–2.1) | 1.9 (1.3–2.5) | |
Clonidine–dexmedetomidine, 1:1 ratio | Synergistic | |||
Observed combination | 0.16 (0.11–0.23)* | |||
Theoretical additive | 0.90 (0.73–1.1) | |||
Figures 4C and D, α2CAR-zKO | Single drug | 5.3 (4.1–6.5) | 4.4 (3.5–5.3) | |
Clonidine–dexmedetomidine, 1:1 ratio | Subadditive | |||
Observed combination | 3.6 (2.2–5.0)* | |||
Theoretical additive | 1.71 (1.3–2.1) |
Significant difference from theoretical additive by Student t test, P < 0.05.
AR = adrenergic receptor; CI = confidence interval; ICR = Institute of Cancer Research; KO = knockout; WT = wild type.